lateral
Sclerosis, referred to as ALS, is commonly known as gradually frozen people. It is an irreversible fatal motor neuron disease, the main symptom of which is the gradual weakness and atrophy of muscles in limbs and trunk. The disease generally progresses rapidly, and the average survival time of more than half of the patients after diagnosis is 3-5 years, and most of them die of respiratory failure caused by respiratory weakness.
drug therapy
Lilutek (Lilutek)
Although ALS is still an incurable disease, since 1999, lirutake, a drug that can delay the progress of ALS, has been included in Japan's medical insurance. Lirutake is suitable for prolonging the life of patients with amyotrophic lateral sclerosis (ALS) or the time when mechanical ventilation is needed. Clinical trials have proved that riluzole can prolong the survival time of als patients. Survival is defined as a surviving patient who does not need intubation for mechanical ventilation and has not undergone tracheotomy.
RADICUT common name: Yida Lavon
From June 2065438 to June 2005, RADICUT, which has been used to treat acute cerebral infarction, was commonly called edaravone, which has been proved to have a significant effect on delaying amyotrophic lateral sclerosis. As a new indication of "ALS therapeutic drug", it was approved in Japan in July.
RADICUT generic name: Edaravone was developed by Mitsubishi Chemical (now Tanabe Mitsubishi Pharmaceutical) and listed on 20 1 1. By 20 1 1, many generic drugs appeared on the market due to the expiration of patents. The core of its mechanism is antioxidation. That is to say, the reduction of regional cerebral blood flow around the infarction can be suppressed by eliminating the free radicals accumulated in the patient.
In human body, edaravone ions are produced by removing hydrogen at α position of carbonyl group. Then it reacts with free radicals to generate edaravone free radicals, and its more stable yoke structure is obtained. It can be used as a free radical scavenger to react with oxygen to obtain 4,5-diketone, and then further hydrolyzed to obtain OPB. Radical cutting, two English words are combined to get "radical cutting", which is a simple and intuitive way of naming drugs in Japan. RADICUT, as a drug for the treatment of acute cerebral infarction, has developed a new indication for ALS with the efforts of pharmaceutical workers, that is, it provides neuroprotective support for the nervous system by scavenging free radicals, potentially delaying the development of the disease or limiting additional damage. Today, there is no better treatment. "For ALS patients, the emergence of RADICUT is like a drowning person seeing a lifeline."